Genetic alterations during treatment of oligometastatic colorectal cancer (GATTACA)

• Conditions: C20; C19; C18; Malignant neoplasm of rectum; Malignant neoplasm of rectosigmoid junction; Malignant neoplasm of colon

• Registration Number: DRKS00006294
• Lead Sponsor: Klinikum der Universität München, Campus Großhadern

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-12
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

1. histologically proven oligometastatic colorectal cancer
(Oligometastatic disease status defined as involving up to 3 organ systems; up to 3 metastases per organ system)
2. Any treatment line irrespective of previous chemotherapy lines
3.Patient treatment recommendation confirmed by an institutional multidisciplinary tumor board (MDT)
4.Metastases amenable to complete ablation/resection using different techniques (radiofrequency ablation, thermoablation, photon beam radiation, surgery, including minimal invasive resections)
5.Age >18 Jahre
6.Life expectancy > 12 months
7. signed and dated consent form

Exclusion Criteria

1. Patients with metastases involving more than 3 organ systems (e.g. liver, lung, bone and retroperitoneal compartment)
2. Patients with peritoneal or pleural metastases
3. Patient having undergone Whipple Operation
4. Second carcinoma, except carcinoma in situ of the cervix or basal cell carcinoma.
5. Pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
There is a proportionality between the fall of the free-circulating tumor DNA 8 weeks after therapy and 16-72 week interval and the progression free survival and / or overall survival. (Check of the degree of response)

Secondary Outcome Measures

Name	Time	Method
Is tumor recurrence (Progression free survival) associated with a different profile of genetic alterations?